Wednesday, June 14, 2023

Brief Blog; PMWC Conference 2024 Includes AI Tracks

 I am happy to be a panelist next winter at the February 2024 Personalized Medicine World Congress in Santa Clara.

I got a conference email today which I am sharing.  They provide an abbreviated agenda of the conference tracks, and highlight some that focus on AI trends.

Separately, see current Bloomberg articles, McKinsey predicts workplace changes here and AI impacts biopharma here.


[From PWMC President Tal Behar]

 As an advocate for advancements in precision medicine and the president of PMWC, I am thrilled to announce the upcoming 23rd installment of the PMWC Conference from January 24th to 26th, 2024, which will delve into the breakthrough use of Large Language Models (LLMs) like ChatGPT, helping drive innovations in precision medicine.

Since its launch last year, ChatGPT has been making waves as the next big leap in artificial intelligence. This cutting-edge technology has the potential to revolutionize communication, research, and access to information, thereby transforming various fields, with healthcare being a key area of focus. By leveraging ChatGPT, healthcare providers can enhance care delivery, improve patient health literacy, facilitate engagement, aid in clinical diagnosis, and alleviate staff burden.

At PMWC 2024, we will explore how ChatGPT and similar LLMs can unlock the full potential of precision medicine. Together, we will address the challenges associated with implementation, including ensuring up-to-date content, incorporating human oversight, mitigating potential data biases, and ensuring compliance with the Health Insurance Portability and Accountability Act (HIPAA)

The PMWC program committee has curated an exciting 3-day schedule that focuses on many of the Precision Medicine related aspects, including AI and ChatGPT themes, that need our attention. This 12-track program, spread across 4 stages over 3 days, has been carefully selected to address the most critical and timely topics in the field, just as in previous years.
Please find an overview of the January 24-26 program here:

• Track 1 – Emerging Therapeutics
     Jan. 24 - Gene & Cell Therapies for Rare Disease: Focuses on important rare disease aspects, such as accelerating approval for small population studies in relation to biomarkers and endpoints, embracing novel clinical trial approaches, and empowering patient advocacy in rare disease therapy.
                Track Chair: Yael Weiss and Peter Marks (FDA)
     o Jan. 25 - Oncology-focused Gene Modified Cell Therapies: Investigates scientific advancements in individualized cell therapeutics for oncology, the discovery of novel targets, logistics and supply chain challenges, and cost considerations for individualized cell therapies.
                Track Chair: Sharon Benzeno (Adaptive Biotechnologies)
     o Jan. 26 - Pharmacogenomics (PGx): Interrogates the state (current and desired) of pharmacogenomic testing in relation to the standardization of clinical laboratory processes, reporting, ordering and reimbursement, and education; along with advancing of PGx in clinical practice. 
               Track Chair: Kelly Claude (St. Jude Children's Research Hospital)

• Track 2 – AI & Data Sciences
     o Jan. 24 - AI and Data Science in Clinical Practice: Investigates the significance of healthcare IT policy, interoperability, and barriers of deployment of AI and data sciences for clinic use; evaluates how healthcare will be transformed with innovative AI applications.
                Track Chair: Russ Cucina (UCSF)
     o Jan. 25 - Real-world Evidence and Data (RWE/D): Looks into incentives to increase data sharing in medical research; the role the FDA plays in regulating and enforcing data sharing; the legal, ethical and regulatory challenges that need to be overcome; Accelerating Drug Development Approvals Using RWE/D.
                Track Chair: William Oh (Mount Sinai)
     o Jan. 26 - AI & Data Sciences in Drug Discovery & Clinical Research: Dives into the potential of Large Language Models (LLMs) such as ChatGPT in medical and life-sciences discovery; the risks and benefits of applying LLMs; optimizing and harmonizing data systems; federated data querying via remote compute infrastructures; how to promote global collaboration for data sharing.
                Track Chair: Gad Getz (Broad Institute)

• Track 3 – Dx & Molecular Profiling in the Clinic
     o Jan. 24 - Oncology Applications: Focuses on aspects such as precision immunotherapy; novel clinical trial design to revolutionize clinical trials; and opportunities and limitations of applying transcriptomics in precision oncology.
                Track Chair: Razelle Kurzrock (Medical College of Wisconsin)
     o Jan. 25 - Women’s Health: Focuses on sex differences and the underlying biology for large studies and for different diseases such as cancer, cardiovascular, and immunology.
                Track Chair: Yoel Sadovsky (University of Pittsburgh) and Noel Bairey Merz (Cedars Sinai Medical Ctr.)
     o Jan. 26 - Infectious Disease: Highlights the current pain points, the population health-level preparedness we need to aim for, and emerging diagnostics and therapeutics with challenges and opportunities in the field of infectious disease.
                Track Chair: Charles Chiu (UCSF)

• Track 4 – Next Generation Technologies
     o Jan. 24 - New Frontiers in Precision Medicine: Brings into focus how public-private partnerships can catalyze transformative health breakthroughs and the role of new private research institutions.
                Track Chair: Keith Yamamoto (UCSF)
     o Jan. 25 - Clinical Utility of Liquid Biopsy: Focuses on the clinical applications of liquid biopsy, including health monitoring and disease prevention, the potential of liquid biopsy for early cancer detection, the role of liquid biopsy in cancer immunotherapy, and multi-omic approaches. The latest technologies and methodologies in liquid biopsy will also be discussed.
                Track Chair: Laura Van’t Veer (UCSF)
     o Jan. 26 - Sequencing and Tech Applications: New Frontiers in Genomic Analysis & Interpretation, The Impact of (New) Sequencing Technologies on Genomics, The Economic Perspective on Genomics, The role of AI in genomics and the regulatory challenges of WGS at the point of care, Multi-omics Approaches of the Future.
                Track Chair: Stacey Gabriel (Broad Institute) & Steve Turner (PacBio)

• Showcase Tracks S1 & S2 - Will cover themes that align with the Track 1-4 program
     o Jan. 24 - 26
     o These company presentations grouped by technology focus will emphasize the upcoming and developed products and services that complement the precision medicine landscape.

Please join us on January 24-26 for PMWC Silicon Valley 2024 at the Santa Clara Convention Center, conveniently located less than 5 miles from the San Jose International Airport (Early Bird Rate)

We are committed to getting the various stakeholders into one room to debate and evaluate the different directions and developments of precision medicine and harness the collective power of the combined expertise in order to drive definite positive change to improve healthcare efficiencies and patient outcomes, for the benefit of a healthier world. Do not miss this unique, first-in-class opportunity to be part of this critical dialogue while hearing first-hand from industry-leading experts how recent advances, opportunities, and challenges will shape medicine and healthcare of the future.


Tal Behar

President & Co-founder, PMWC
PMWC 2024 Silicon Valley - January 24-26, 2024

The Precision Medicine World Conference (PMWC)